2m 2m 2m 2m 2m 2m 2m
QUINCE THERAP (QNCX)
NASDAQ
$1.02-$0.01 (-1.36%)
Price as of Jun 03, 2026 7:59 PM EDT- $22.5MMarket Cap
- -90.55%1-Year Change
- BiotechnologyIndustry
QUINCE THERAP (QNCX)
$1.02-$0.01 (-1.36%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 125.0M N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 125.0M N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -35.4M +90.33% | -18.6M +96.78% | -9.4M -62.48% | -25.2M -58.59% | |
Depreciation and Amortization Expense | 142,000 -23.66% | 186,000 -42.24% | 322,000 +57.84% | 204,000 -40.70% | |
Total Operating Expenses | 58.1M +1.37% | 57.3M +65.47% | 34.6M -33.44% | 52.0M -42.41% | |
Operating Profit | -58.1M +1.37% | -57.3M +65.47% | -34.6M -33.44% | -52.0M -42.41% | |
Interest Income | 1.2M -57.53% | 2.9M -15.78% | 3.5M +225.66% | 1.1M +72.26% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 1.2M -57.53% | 2.9M -15.78% | 3.5M +225.66% | 1.1M +72.26% | |
Total Nonoperating Income and Expense | 486,000 +171.89% | -676,000 +562.75% | -102,000 -89.77% | -997,000 +303.64% | |
Income before Taxes | -80.8M +42.34% | -56.7M +79.66% | -31.6M -39.20% | -51.9M -42.49% | |
Income Taxes | 3.2M +3,594.25% | 87,000 -55.84% | 197,000 +169.37% | -284,000 N/A | |
Extraordinary Items | 0 N/A | 0 -100.00% | 100,000 N/A | 0 N/A | |
Net Income | -84.0M +47.78% | -56.8M +81.07% | -31.4M -39.25% | -51.7M -42.56% | |
Net Income from Continuing Operations Applicable to Common | -84.0M +47.78% | -56.8M +81.07% | -31.4M -39.25% | -51.7M -42.56% | |
Basic EPS and Net Income | -1.68 +28.24% | -1.31 +55.95% | -0.84 -45.45% | -1.54 -49.17% | |
Diluted EPS and Net Income | -1.68 +28.24% | -1.31 +55.95% | -0.84 -45.45% | -1.54 -49.17% | |
Basic Weighted Average Shares | 50.1M +15.80% | 43.3M +16.18% | 37.2M +11.17% | 33.5M +12.71% | |
Diluted Weighted Average Shares | 50.1M +15.80% | 43.3M +16.18% | 37.2M +11.17% | 33.5M +12.71% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 5.8M -6.49% | 6.2M -70.07% | 20.8M -53.45% | 44.6M -36.06% | |
Short-Term Investments | N/A N/A | 34.6M -36.34% | 54.3M +19.09% | 45.6M +22.99% | |
Cash and Cash Equivalents and Short-Term Investments | 5.8M -85.76% | 40.8M -45.66% | 75.1M -16.77% | 90.2M -15.56% | |
Total Current Assets | 22.9M -48.01% | 44.0M -43.14% | 77.4M -17.40% | 93.7M -16.05% | |
Accumulated Depreciation | 844,000 +32.08% | 639,000 +26.04% | 507,000 +174.05% | 185,000 -80.71% | |
Property and Plant and Equipment and Net | 595,000 +88.89% | 315,000 +34.62% | 234,000 -40.46% | 393,000 +49.43% | |
Total Long-Term Assets | 1.8M -81.64% | 9.6M +13.34% | 8.5M N/A | 0 -100.00% | |
Total Assets | 93.5M -18.30% | 114.5M -31.82% | 167.9M +61.58% | 103.9M -22.01% | |
Income Taxes Payable | 0 -100.00% | 5.0M -6.43% | 5.3M +2,038.71% | 248,000 N/A | |
Total Short-Term Debt | 18.0M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 43.2M +493.93% | 7.3M -23.97% | 9.6M +211.89% | 3.1M -78.42% | |
Total Long-Term Debt | 0 -100.00% | 14.3M +6.64% | 13.4M N/A | N/A N/A | |
Total Long-Term Liabilities | 1.6M +129.20% | 685,000 +16.70% | 587,000 +18.35% | 496,000 +18.10% | |
Total Liabilities | 129.2M +53.25% | 84.3M +1.83% | 82.8M +2,396.71% | 3.3M -77.35% | |
Retained Earnings | -460.5M +22.31% | -376.5M +17.78% | -319.6M +10.89% | -288.3M +21.83% | |
Total Stockholders Equity | -35.7M -218.47% | 30.1M -64.57% | 85.1M -15.42% | 100.6M -15.17% | |
Total Shares Outstanding | 55.7M +26.64% | 44.0M +2.39% | 43.0M +18.92% | 36.1M +20.16% | |
Cash Flow | |||||
Cash from Operating Activities | -41.4M +29.84% | -31.9M +74.42% | -18.3M -58.46% | -44.0M -30.02% | |
Capital Expenditures | 352,000 +36.96% | 257,000 +60.63% | 160,000 +20.30% | 133,000 -26.11% | |
Cash from Investing Activities | 23.2M +6.02% | 21.9M +480.48% | -5.8M -131.99% | 18.0M -69.46% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 17.9M +475.06% | -4.8M -3,439.16% | 143,000 -79.77% | 707,000 -89.62% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -27.70% N/A | N/A N/A | |
Return on Assets | -80.75% +100.62% | -40.25% +74.29% | -23.09% -47.00% | -43.57% -21.84% | |
Return on Equity | 3,016.49% +3,158.26% | -98.63% +191.76% | -33.81% -28.29% | -47.14% -23.78% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 0.53 -91.25% | 6.05 -25.21% | 8.09 -73.52% | 30.55 +289.03% | |
Cash Ratio | 0.13 -84.25% | 0.85 -60.63% | 2.17 -85.07% | 14.53 +196.29% | |
Debt-to-Equity Ratio | -0.50 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.19 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow